Skip to main content
Premium Trial:

Request an Annual Quote

Deep Bio, Healthcare Konnect Ink Distribution Agreement for Prostate Cancer Pathology Software

NEW YORK ─ Healthcare Konnect and Deep Bio said Tuesday that they have entered into a distribution agreement for Deep Bio's artificial intelligence-based DeepDx Prostate software, with initial distribution targets to include Swiss, Moroccan, Algerian, Tunisian, and Egyptian healthcare institutions.

Financial and other terms of the agreement were not disclosed.

Deep Bio's DeepDx Prostate supports pathologists who are identifying cancerous areas and grading severity on whole-slide images of hematoxylin- and eosin-stained prostate core needle biopsy samples, the firms said.

The software, which detects prostate cancer and grades its severity based on the Gleason scoring system, has shown high performance in clinical validation studies and is currently used in numerous laboratories for quality control and R&D, they added.

"We believe that DeepDx Prostate is a tool that can help pathologists provide more accurate and consistent diagnosis of prostate cancer," Marwan Senhaji, CEO of Geneva-based Healthcare Konnect, a medical device distribution company, said in a statement.

Healthcare Konnect is currently starting discussions with institutions in Switzerland and North Africa for the distribution of DeepDx Prostate, he added.

Seoul, South Korea-based Deep Bio is also collaborating with universities and laboratories to develop AI-based diagnostic models for other cancer types including breast and bladder cancers, and lymph node metastasis, the firms said.

In July, Gestalt Diagnostics and Deep Bio announced a strategic relationship to develop an integrated workflow to use artificial intelligence algorithms on Gestalt's digital pathology platform.